Oryzon Genomics S.A. (BME:ORY)
3.220
+0.040 (1.26%)
At close: Feb 26, 2026
Oryzon Genomics Employees
Oryzon Genomics had 47 employees as of June 30, 2025. The number of employees did not change since the number was reported on December 31, 2024.
Employees
47
Change
n/a
Growth
n/a
Revenue / Employee
€156,570
Profits / Employee
€58,639
Market Cap
250.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 47 | 0 | - |
| Dec 31, 2024 | 47 | 1 | 2.17% |
| Dec 31, 2023 | 46 | 2 | 4.78% |
| Dec 31, 2022 | 44 | 0 | - |
| Dec 31, 2021 | 44 | 1 | 1.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Grifols | 23,800 |
| Laboratorios Farmaceuticos Rovi | 2,188 |
| Almirall | 2,084 |
| Atrys Health | 2,016 |
| Faes Farma | 1,894 |
| Clínica Baviera | 1,847 |
| Laboratorio Reig Jofre | 1,426 |
| Prim, S.A. | 902 |
Oryzon Genomics News
- 2 days ago - ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia - Benzinga